| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 481.6 | 530.3 |
| Profit before tax | -20.9 | -22.6 |
| Net income | -80.8 | -28.3 |
| EPS (diluted, $ a share) | $-0.13 | $-0.04 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -9.2% |
|---|---|
| Operating margin | 8.3% |
10-Q filed with the SEC, NYSE: CLVT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Clarivate PLC: key numbers
- Share price
- $2.19Close, Nov 17
- Market cap
- $1.4B
- Shares outstanding
- 639.9MLatest SEC cover page
- Sector
- Technology
- Industry
- Services-Computer Processing & Data PreparationSIC 7374
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Clarivate PLC
All →Clarivate $533M Debt Financing with Clarivate Science Holdings Corporation
Clarivate Plc announced the final results of cash tender offers to purchase its 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029. The company increased the acceptance amount and will purchase a total aggregate principal amount of $533 million of the notes. The 2028 and 2029 notes were accepted at proration factors of approximately 67.9% and 45.5%, respectively.
- Value
- $533M
- Counterparty
- Clarivate Science Holdings Corporation
Clarivate $533M Debt Financing
Clarivate Plc's subsidiary, Clarivate Science Holdings Corporation, announced the pricing terms for its cash tender offers to repurchase up to $533 million in aggregate principal amount of its outstanding 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029. The company exercised its right to increase the purchase caps for each series of notes by 2% of the outstanding aggregate principal amount.
- Value
- $533M
Clarivate $500M Debt Financing with Clarivate Science Holdings Corporation
Clarivate Plc's subsidiary, Clarivate Science Holdings Corporation, has launched cash tender offers to repurchase up to $500 million in aggregate principal amount of its outstanding 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029. The offers include specific series caps of $400 million for the 2028 notes and $100 million for the 2029 notes, aimed at managing the company's debt profile.
- Value
- $500M
- Counterparty
- Clarivate Science Holdings Corporation
Clarivate Financial Results
Clarivate reported third quarter 2026 results with total revenues of $567.9 million and a net loss of $80.8 million, impacted by a $62.2 million goodwill impairment charge related to the Life Sciences & Healthcare segment. The company completed the divestiture of its Life Sciences & Healthcare segment on October 6, 2026, and updated its full-year 2026 financial outlook to reflect the transaction.
“Third quarter results continued to improve across key metrics, including organic recurring revenue growth and the return to positive ACV growth in the Intellectual Property segment. We also achieved a major milestone with the early close of the Life Sciences & Healthcare segment divestiture, positioning us for enhanced value creation in our two market-leading segments, Academia & Government and Intellectual Property. The growing commercial traction and customer validation from our AI-led innovation within A&G and IP give us confidence in our ability to deliver on our commitments of accelerating sustained organic growth, expanding free cash flow and reducing leverage.”
Matti Shem Tov, Chief Executive Officer
“We are seeing the benefits of disciplined execution across the business, with improving growth trends, strong margins and continued free cash flow generation. Our focus remains on translating organic growth into sustainable earnings and free cash flow, while maintaining a disciplined approach to capital allocation. Looking ahead, we are well positioned to further strengthen our financial profile and enhance our financial flexibility.”
Michael Easton, Executive Vice President and Chief Financial Officer
Clarivate Divestiture to Altaris, LLC for $600M
Clarivate Plc completed the sale of its Life Sciences and Healthcare (LS&H) business to an affiliate of Altaris, LLC for an aggregate purchase price of $600 million. The consideration consists of $500 million in cash, a $75 million unsecured senior note, and $25 million in deferred cash consideration. The transaction represents a strategic shift for Clarivate and will be classified as discontinued operations.
- Value
- $600M
- Counterparty
- Altaris, LLC
Clarivate Divestiture to Altaris, LLC for $600M
Clarivate Plc completed the sale of its Life Sciences and Healthcare business to an affiliate of Altaris, LLC for total consideration of $600 million. The deal consists of $500 million in cash, a $75 million unsecured senior note, and $25 million in deferred cash consideration. The divestiture is intended to sharpen the company's focus on its Academia & Government and Intellectual Property segments while using proceeds to reduce debt.
- Value
- $600M
- Counterparty
- Altaris, LLC